Efficacy of Microbiome Manipulation Strategies Fecal Microbial Transplant or Anti-inflammatory Diet or Both With Advanced Therapies BiOlOgics and Small Molecules to Break the Therapeutic Ceiling in Active Ulcerative Colitis BOOST-UC A Multicenter Double Blind Factorial Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 220
- 试验地点
- 8
- 主要终点
- Proportion of Patients Achieving Clinical Remission and Endoscopic Response at 10 weeks
研究概览
简要总结
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by superficial mucosal inflammation. Treatment aims to achieve and maintain remission, improve quality of life, and minimize complications. Advanced therapies, including biologics and small molecules, have significantly improved UC management by targeting specific inflammatory pathways. However, due to the multifactorial nature of UC-driven by genetic, environmental, and microbial factors-many patients do not achieve sustained remission, highlighting a therapeutic ceiling. Gut microbial dysbiosis and immune dysregulation are central to UC pathogenesis, with diet playing a critical role in influencing the gut microbiome. While biologics and small molecules have limitations, innovative approaches like combining fecal microbiota transplantation (FMT) and dietary interventions with advanced therapies show promise. FMT restores microbial balance, modulates immunity, and reduces inflammation, while dietary modifications, such as anti-inflammatory diets, enhance FMT efficacy by creating a favorable environment for donor microbiota engraftment. The present study is designed to evaluate the efficacy of three different microbiome manipulation strategies- FMT, AID and FMT + AID in combination with advanced therapies in patients with active UC in a 2X2 factorial trial design. Patients would be randomized into four different arms: FMT, AID, FMT+AID and placebo. The advanced therapies (biologics or small molecules) would be given in all four arms as standard therapy. With this design the trial would answer two important questions: a) efficacy of combination treatment with advanced therapies and microbiome manipulation strategies in active UC, and b) comparative efficacy of different microbiome manipulation strategies.
详细描述
This study is a multicenter, randomized, factorial-design, double-blind, controlled trial investigating the effects of fecal microbiota transplantation (FMT) and dietary interventions in patients with mild to moderate, treatment-naïve, active inflammatory bowel disease. The trial is being conducted across multiple clinical centers, with a central microbiome analysis facility.
Randomization and Blinding:
Randomization: Centralized, computerized randomization is employed to ensure balanced treatment allocation. The permuted block method, along with stratification based on disease characteristics, ensures equal distribution across intervention arms Blinding: Patients, investigators collecting clinical data, and endoscopic video assessors are blinded to treatment allocation. The dietitian and endoscopist performing FMT (or sham FMT) are unblinded
Intervention Arms:
Participants are assigned to one of four treatment arms:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (age 18 to 75 years) patients
- •Patients with active UC (defined as mMS equal or greater than 3 with rectal bleed score equal or greater than 1 and Endoscopic Mayo score equal or greater than 2 documented within 3 months of randomization or mild symptoms with high inflammatory burden or poor prognostic features).
- •Any disease extent E1, E2 or E
- •Patients with Proctitis will be limited to 25 percent of the entire pool of patients.
- •Patients with an inadequate response, loss of response, or intolerance to conventional therapies example, aminosalicylates, corticosteroids, immunosuppressants or advanced therapies including but not limited to anti TNF alpha agents, anti-integrins, anti IL 12 or IL 23 agents, anti IL 23 agents, JAK inhibitors, or S1P receptor modulators. The last administration of any such treatment must have occurred at least five half-lives prior to randomization.
- •Confirmed diagnosis of UC. The diagnosis must be confirmed by endoscopic and histologic evidence and corroborated by a histopathology report
- •Subjects who are willing and able to comply with treatment plan, laboratory tests, daily bowel movement diary call and other study procedures
- •Subjects who are willing to provide a written informed consent for FMT
- •Agree to adhere to the diet schedule
- •Infective colitis ruled out Biopsy showing crypt architecture distortion or basal plasmacytosis, OR two sigmoidoscopies, at least 7 days apart showing evidence of endoscopic activity
排除标准
- •Hospitalization of exacerbation of UC requiring intravenous corticosteroids
- •Patients already on biologics (anti-tumor necrosis factor inhibitors) or small molecules (tofacitinib) for equal or more than 2 weeks.
- •Clinical signs of fulminant colitis or toxic megacolon
- •Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridioides difficile toxin or CMV (histology or IHC and or tissue PCR) at screening. (The patients with positive assay will be treated appropriately and tests will be repeated. Those with negative assay and persistent activity will be included in the study.)
- •Active or inadequately treated infections, including Mycobacterium tuberculosis.
- •Presence of IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's Disease.
- •Patients infected with human immunodeficiency virus (HIV)
- •Patients with current or past history of malignancy.
- •Patients with current or recent history of clinically severe, progressive, or uncontrolled renal, hepatic, Hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease.
- •Pregnant females
结局指标
主要结局
Proportion of Patients Achieving Clinical Remission and Endoscopic Response at 10 weeks
时间窗: 10 weeks
Proportion of patients having- 1. Clinical remission which is defined as the Modified Mayo Score (mMS) \< 2 \\ mMS- Full Title: Modified Mayo Score Range: 0 to 12 Higher Scores = Worse Outcome (A score of 0 represents no disease activity, and a score of 12 represents the most severe disease activity.) 2. Endoscopic response which is defined as Mayo Endoscopic Score (MES) by 1 point MES- Full Title: Mayo Endoscopic Score Range: 0 to 4 Higher Scores = Worse Outcome (A score of 0 represents normal endoscopic findings, and a score of 4 represents severe mucosal damage.
Proportion of patients having clinical remission and endoscopic remission at week 48
时间窗: 48 weeks
Proportion of patients having- 1. Clinical remission which is defined as the Modified Mayo Score (mMS) \< 2 mMS- Full Title: Modified Mayo Score Range: 0 to 12 Higher Scores = Worse Outcome (A score of 0 represents no disease activity, and a score of 12 represents the most severe disease activity.) 2. Endoscopic response which is defined as Mayo Endoscopic Score (MES) by 1 point MES- Full Title: Mayo Endoscopic Score Range: 0 to 4 Higher Scores = Worse Outcome (A score of 0 represents normal endoscopic findings, and a score of 4 represents severe mucosal damage.
次要结局
- Proportion of Patients Achieving Biomarker Remission at Week 10(10 weeks)
- Proportion of patients having clinical response at week 10(10 weeks)
- Dynamics of microbiome engraftment at week 10(10 weeks)
- Proportion of patients having clinical remission at week 10(10 weeks)
- Proportion of Patients Achieving Endoscopic Response at Week 10(10 weeks)
- Proportion of Patients Achieving Histologic Remission at Week 10(10 weeks)
- Proportion of Patients achieving Symptomatic Response at Week 10(10 weeks)
- Proportion of Patients achieving Symptomatic Remission at week 10(10 weeks)
- Proportion of Patients Achieving Endoscopic Remission at Week 10(10 weeks)
- Proportion of Patients Experiencing Adverse Events at Week 10(10 weeks)
- Fecal Microbiome and Metabolite Signature at Week 10(10 weeks)
- Proportion of patients having clinical response at week 48(48 weeks)
- Proportion of patients having clinical remission at week 48(48 weeks)
- Proportion of Patients Achieving Symptomatic Response at Week 48(48 weeks)
- Proportion of Patients achieving Symptomatic Remission at Week 48(48 weeks)
- Proportion of Patients achieving Endoscopic Response at Week 48(48 weeks)
- Proportion of Patients achieving Endoscopic Remission at Week 48(48 weeks)
- Proportion of Patients achieving Histologic Remission at Week 48(48 weeks)
- Proportion of Patients Achieving Biomarker Remission at Week 48(48 weeks)
- Fecal Microbiome and Metabolite Signature at Week 48(48 weeks)
- Dynamics of microbiome engraftment at week 48(48 weeks)
- Proportion of Patients Experiencing Adverse Events at Week 48(48 weeks)
- Proportion of patients having adverse events at week 6(6 weeks)
- Proportion of patients having adverse events at week 26(26 weeks)
研究者
Prof. Vineet Ahuja
Professor
All India Institute of Medical Sciences, New Delhi